LIBTAYO 350 mg, solution à diluer pour perfusion

USDailyMed:Cemiplimab AU:D L01FF06(WHO) AU:S4(Prescription only)CA:℞-only/ Schedule DUS:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) 1801342-60-8 DB14707 none 6QVL057INT D11108 Cemiplimab, sold under the brand nameLibtayo, is amonoclonal antibodymedication used for the treatment ofsquamous cell skin​​​‍​​‍​​​​‍​​‍‍ cancer.Cemiplimab belongs to a class of drugs that binds to theprogrammed death receptor-1(PD-1),blocking the PD-1/PD-L1 pathway. The most common side effects include fatigue, rash, diarrhea, musculoskeletal pain, and nausea. It was approved for medical use in the United States in September 2018,in the European Union in June 2019.and in Australia in July 2020. Cemiplimab is the first approval by the USFood and Drug Administrationof a medication specifically for advanced cutaneous squamous cell carcinoma.Cemiplimab is a therapeutic alternative on theWorld Health Organization's List of Essential Medicines.